Nvwm LLC Has $1.46 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Nvwm LLC raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 74,534.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 17,166 shares of the medical research company’s stock after buying an additional 17,143 shares during the period. Nvwm LLC’s holdings in Edwards Lifesciences were worth $1,463,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $266,000. CW Advisors LLC boosted its holdings in Edwards Lifesciences by 92.5% in the second quarter. CW Advisors LLC now owns 12,241 shares of the medical research company’s stock valued at $958,000 after acquiring an additional 5,882 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Edwards Lifesciences by 43.2% in the second quarter. EverSource Wealth Advisors LLC now owns 3,180 shares of the medical research company’s stock worth $249,000 after purchasing an additional 959 shares during the period. Amundi increased its position in Edwards Lifesciences by 18.6% in the second quarter. Amundi now owns 3,461,129 shares of the medical research company’s stock worth $266,576,000 after purchasing an additional 541,943 shares during the period. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in Edwards Lifesciences by 51.9% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 1,571 shares of the medical research company’s stock worth $123,000 after purchasing an additional 537 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on EW. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday. Barclays reiterated an “overweight” rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, Citigroup reaffirmed a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.96.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,704,682.56. This represents a 51.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 84,398 shares of company stock valued at $7,054,310. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $80.85 on Friday. The stock has a market cap of $46.61 billion, a P/E ratio of 44.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.95. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The stock’s 50-day moving average price is $81.65 and its two-hundred day moving average price is $81.80. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s revenue was up 13.3% compared to the same quarter last year. During the same period last year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.